Professor, Internal Medicine, Mayo Medical School
Cardiology
Dr. Horng H. Chen, MD
|
|
Give Review
Horng Chen practices Cardiology. He over the years received 2 awards: "Elected Member" and "Fellow (FACC)". Dr. Horng H. Chen has written publications. He has 72 publications published with PubMed. The lastest publication is: 'Chronic Peptide Therapy With B-Type Natriuretic Peptide in Patients With Preclinical Diastolic Dysfunction (Stage B Heart Failure).' Horng Chen is registered with Medicare.
Publications
- Chronic Peptide Therapy With B-Type Natriuretic Peptide in Patients With Preclinical Diastolic Dysfunction (Stage B Heart Failure).
- Natriuretic peptides as a novel target in resistant Hypertension.
- Galectin-3 in Heart Failure With Preserved Ejection Fraction: A RELAX Trial Substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity i...
- Is there still a role for low-dose dopamine use in Acute heart failure?
- ROSE-AHF and Lessons Learned.
- A dosage-dependent pleiotropic role of Dicer in prostate cancer growth and metastasis.
- Dopamine vs nesiritide for Acute heart failure with renal dysfunction--reply.
- Pre-clinical diastolic dysfunction.
- Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction: The ROSE Acute Heart Failure Randomized Trial.
- Rationale and design of a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of B-type natriuretic Peptide for the preservation of le...
- Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in Heart failure with preserved ejection fraction: a randomized clinical trial.
- CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the Heart.
- Ultrafiltration in decompensated Heart failure with cardiorenal syndrome.
- Novel protein therapeutics for systolic Heart failure: chronic subcutaneous B-type natriuretic Peptide.
- Human Hypertension Is Characterized by a Lack of Activation of the Antihypertensive Cardiac Hormones ANP and BNP.
- Experimental Mild Renal Insufficiency Mediates Early Cardiac Apoptosis, Fibrosis and Diastolic Dysfunction: A Kidney - Cardiac Connection.
- Impaired natriuretic and renal endocrine response to Acute volume expansion in pre-clinical systolic and diastolic dysfunction.
- Evolving Treatment Strategies for Management of Cardiorenal Syndrome.
- Novel natriuretic peptides: new compounds and new approaches.
- β-trace protein versus cystatin C: which is a better surrogate marker of renal function versus prognostic indicator in cardiovascular Diseases?
- The aging Heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic Peptide.
- A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated Acute hypertension.
- Is cystatin C an important prognostic marker independent of renal function?
- B-type natriuretic peptide and extracellular matrix protein interactions in human cardiac fibroblasts.
- Regulation of circulating progenitor cells in left ventricular dysfunction.
- The development of Heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study.
- Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide.
- Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects.
- Changes in diastolic dysfunction in diabetes mellitus over time.
- Local renal delivery of a natriuretic peptide a renal-enhancing strategy for B-type natriuretic peptide in overt experimental Heart failure.
- Atrial natriuretic peptide for the prevention of contrast-induced nephropathy: what's old is new but at the right dose and duration of therapy!
- Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and Acute actions in angiotensin II-mediated hypertension.
- B-type natriuretic peptide: beyond a diagnostic.
- The role of natriuretic peptides in Heart failure.
- The effects of nesiritide on renal function and diuretic responsiveness in Acutely decompensated heart failure patients with renal dysfunction.
- Targeting the kidney in Acute decompensated heart failure: conventional diuretics and renal-acting vasodilators.
- Nesiritide in Acute decompensated heart failure: current status and future perspectives.
- Distinct roles for renal particulate and soluble guanylyl cyclases in preserving renal function in experimental Acute heart failure.
- Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardioPulmonary-bypass surgery: a double-blind placebo-control...
- Usefulness of brain natriuretic peptide levels in the clinical evaluation of patients with hypertrophic Cardiomyopathy.
- Heart failure: a state of brain natriuretic peptide deficiency or resistance or both!
- Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular Disease.
- Pathophysiology of volume overload in Acute heart failure syndromes.
- Lack of activation of molecular forms of the BNP system in human grade 1 Hypertension and relationship to cardiac hypertrophy.
- Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improv...
- Therapeutic potential for existing and novel forms of natriuretic peptides.
- Natriuretic peptides as regulators of Myocardial structure and function: pathophysiologic and therapeutic implications.
- Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with Acute decompensated heart failure and renal d...
- Exertional changes in circulating cardiac natriuretic peptides in patients with suggested Coronary artery disease.
- Association of B-type natriuretic peptide activation to left ventricular end-systolic remodeling in organic and functional Mitral regurgitation.
- Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure.
- Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental Heart failure.
- 76-year-old woman with chest pain.
- Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental Heart failure.
- Subcutaneous administration of the cardiac hormone BNP in symptomatic human Heart failure.
- Endothelin A receptor antagonism in experimental congestive Heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention.
- Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of Acute diuretic therapy in human heart failure.
- Use of plasma brain natriuretic peptide concentration to aid in the diagnosis of Heart failure.
- Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases.
- Diastolic Heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria.
- Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide.
- Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and Acute vasopeptidase inhibition.
- Cardiotrophin-1 stimulation of cardiac fibroblast growth: roles for glycoprotein 130/leukemia inhibitory factor receptor and the endothelin type A receptor.
- Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive Heart failure.
- Intact Acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure.
- Effect of cardiac resynchronization therapy on broad neurohormone biomarkers in Heart failure.
- Diuretic strategies in patients with Acute decompensated heart failure.
- Renal and humoral pathophysiological actions of angiotensin II in congestive Heart failure.
- Progression of preclinical diastolic dysfunction to the development of symptoms.
- Leukemia inhibitory factor is augmented in the Heart in experimental Heart failure.
- Cell surface protein disulfide isomerase regulates natriuretic Peptide generation of cyclic guanosine monophosphate.
Procedures Preformed
- Automatic Implantable Cardioverter Defibrillator (ICD) Implantation
- Cardiac Catheterization (incl. Coronary Angiography)
- Cardiac Imaging
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- View All
Conditions Treated
- Acute Venous Embolism Thrombosis
- Aneurysm and Dissection of Heart
- Angina and Acute Coronary Syndrome
- Aortic Aneurysm
- View All
Doctors Specialties
- Cardiology
Accepted Insurances
Awards
- Elected Member
- Fellow (FACC)
Education
-
Mayo School of Graduate Medical Education -
Royal College of Surgeons Ireland
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1073599320 | |
| NPPES Provider LastName | CHEN | |
| NPPES Provider FirstName | HORNG | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Cardiology | |
| Total Claim Count | 20.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1073599320 |
| Last Name Of The Provider | CHEN |
| First Name Of The Provider | HORNG |
| View All |
Similar Doctors
|
|
Dr. Sudip Nanda, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark W. Kolasa, MD |
|
|
Dr. Thomas J. Bunch, MD |
|
|
Dr. Jae K. Oh, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. R Thomas Tilbury, MD |
|
|
Dr. Erik L. Ritman, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Rekha Mankad, MD
This Doctor is OpenDoctor Recommended.
|